Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Transitional Cell | 4 | 2024 | 45 | 1.860 |
Why?
|
| Kidney Neoplasms | 5 | 2026 | 173 | 1.820 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2024 | 108 | 1.600 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2026 | 114 | 1.390 |
Why?
|
| Neoplasms | 6 | 2025 | 1367 | 1.330 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2026 | 36 | 1.200 |
Why?
|
| Immunotherapy | 4 | 2025 | 274 | 1.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 250 | 0.970 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2026 | 197 | 0.790 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 234 | 0.730 |
Why?
|
| Catheter Ablation | 1 | 2022 | 156 | 0.650 |
Why?
|
| Telemedicine | 1 | 2023 | 363 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 464 | 0.490 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 704 | 0.470 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 140 | 0.390 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 182 | 0.370 |
Why?
|
| Biomedical Research | 1 | 2013 | 262 | 0.310 |
Why?
|
| Humans | 18 | 2026 | 65141 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 373 | 0.230 |
Why?
|
| Thiohydantoins | 1 | 2025 | 1 | 0.230 |
Why?
|
| Thyroid Neoplasms | 1 | 2026 | 87 | 0.230 |
Why?
|
| Androstenes | 1 | 2025 | 9 | 0.230 |
Why?
|
| Urologic Neoplasms | 2 | 2024 | 19 | 0.220 |
Why?
|
| Antihypertensive Agents | 1 | 2026 | 179 | 0.220 |
Why?
|
| Medical Oncology | 1 | 2025 | 69 | 0.210 |
Why?
|
| Disease-Free Survival | 1 | 2024 | 244 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 50 | 0.210 |
Why?
|
| Perioperative Care | 1 | 2024 | 87 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 34 | 0.200 |
Why?
|
| Blood Pressure | 1 | 2026 | 526 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 128 | 0.200 |
Why?
|
| Safety-net Providers | 1 | 2023 | 31 | 0.190 |
Why?
|
| Microwaves | 1 | 2022 | 14 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2024 | 191 | 0.190 |
Why?
|
| Female | 9 | 2026 | 34030 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 644 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2026 | 5790 | 0.180 |
Why?
|
| Hematuria | 1 | 2021 | 23 | 0.170 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 23 | 0.170 |
Why?
|
| Hypertension | 1 | 2026 | 612 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 62 | 0.160 |
Why?
|
| Nephrectomy | 1 | 2021 | 92 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2021 | 67 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2025 | 493 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 801 | 0.160 |
Why?
|
| Middle Aged | 8 | 2026 | 18273 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 875 | 0.150 |
Why?
|
| Decision Making | 1 | 2023 | 418 | 0.150 |
Why?
|
| Palliative Care | 1 | 2021 | 249 | 0.140 |
Why?
|
| Vaccination | 1 | 2021 | 377 | 0.140 |
Why?
|
| Pandemics | 1 | 2023 | 675 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2020 | 110 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2018 | 38 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2018 | 32 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 190 | 0.130 |
Why?
|
| Aged | 6 | 2026 | 14963 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2018 | 576 | 0.120 |
Why?
|
| Pregnancy | 1 | 2023 | 2374 | 0.120 |
Why?
|
| Male | 7 | 2026 | 31055 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 369 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2014 | 6 | 0.110 |
Why?
|
| Gastrointestinal Hormones | 1 | 2014 | 10 | 0.110 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2014 | 22 | 0.100 |
Why?
|
| Pyrroles | 1 | 2014 | 50 | 0.100 |
Why?
|
| Bevacizumab | 1 | 2014 | 60 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2014 | 81 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 112 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2014 | 78 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 82 | 0.100 |
Why?
|
| Indazoles | 1 | 2013 | 19 | 0.100 |
Why?
|
| Immune System | 1 | 2014 | 132 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 49 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 205 | 0.090 |
Why?
|
| Imidazoles | 1 | 2013 | 82 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6865 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2014 | 208 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 296 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Cytokines | 1 | 2014 | 952 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1480 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 5614 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 354 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 4812 | 0.070 |
Why?
|
| Adolescent | 1 | 2018 | 6306 | 0.060 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2026 | 43 | 0.060 |
Why?
|
| Pyrimidinones | 1 | 2025 | 18 | 0.060 |
Why?
|
| Phenylurea Compounds | 1 | 2025 | 32 | 0.060 |
Why?
|
| Animals | 2 | 2014 | 21333 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 991 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2024 | 95 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2025 | 335 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1222 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 102 | 0.040 |
Why?
|
| Brachiocephalic Trunk | 1 | 2020 | 15 | 0.040 |
Why?
|
| Adult | 1 | 2018 | 17358 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 196 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 128 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 79 | 0.040 |
Why?
|
| Mice | 1 | 2014 | 11114 | 0.040 |
Why?
|
| Femoral Artery | 1 | 2020 | 104 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2020 | 106 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2020 | 181 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1219 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 1785 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2484 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 11 | 0.020 |
Why?
|
| Nitriles | 1 | 2011 | 82 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 110 | 0.020 |
Why?
|
| Triazoles | 1 | 2011 | 63 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 130 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 222 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5430 | 0.020 |
Why?
|